Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy.

MLA

Shi, Zhan, et al. “Lymphocyte-to-C Reactive Protein Ratio Is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy.” Journal of Hepatocellular Carcinoma, vol. 11, Feb. 2024, pp. 305–16. EBSCOhost, https://doi.org/10.2147/JHC.S452424.

APA

Shi, Z., Zhu, S., Jin, Y., Qi, L., Zhou, M., Zhou, Z., Zhang, J., Liu, B., & Shen, J. (2024). Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy. Journal of Hepatocellular Carcinoma, 11, 305–316. https://doi.org/10.2147/JHC.S452424

Chicago

Shi, Zhan, Sihui Zhu, Yuncheng Jin, Liang Qi, Mingzhen Zhou, Ziyan Zhou, Juan Zhang, Baorui Liu, and Jie Shen. 2024. “Lymphocyte-to-C Reactive Protein Ratio Is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy.” Journal of Hepatocellular Carcinoma 11 (February): 305–16. doi:10.2147/JHC.S452424.